NovalGen Appoints Dr Laurent Fischer as Chair of the Board

LONDON, May 18, 2026 (GLOBE NEWSWIRE) -- NovalGen today announced the appointment of Dr Laurent Fischer, a globally recognized biopharmaceutical executive, as Non-Executive Chair of the Board of Directors with immediate effect. Dr Fischer brings more than 25 years of CEO and board leadership across public and private biotechnology companies, with a distinguished track record of advancing innovative therapies from discovery through approval and commercialization. His appointment marks an important milestone as NovalGen advances its next-generation AutoRegulation immunotherapy platform and lead asset, NVG-222, into later-stage development.
Dr Fischer has served as Chief Executive Officer of five biopharmaceutical companies spanning oncology, ophthalmology, rare disease, and virology. He h